ClinicalTrials.gov
ClinicalTrials.gov Menu

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01425970
Recruitment Status : Terminated (Termination of study was due to safety reasons)
First Posted : August 30, 2011
Last Update Posted : November 4, 2015
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : August 2013
  Actual Study Completion Date : August 2013
  Certification/Extension First Submitted : September 23, 2015